Maamer M, Aurousseau M, Colau J C
Int J Tissue React. 1987;9(2):135-45.
The results of an experimental and clinical study on the benzydamine binding and distribution in vaginal mucosa are presented, employing benzydamine solution for gynaecological use. When applied first to rats, the mean amount of the drug in their vaginal mucosa became 3.65 +/- 2.99 micrograms/g of fresh tissue with a significant difference between control and treated animals, without detectable amounts in the plasma. When applied to humans, the mean amount of benzydamine assayed in 17 specimens of vaginal mucosa was 9.72 +/- 6.24 micrograms/g. It was greater than the range of animal anti-inflammatory concentration (2-8 micrograms/g) established by pharmacological studies on this drug and justified the local benefits from benzydamine treatment of vaginal inflammation. Benzydamine assayed in seven volunteers with healthy vaginas showed that the drug cannot be detected in the plasma.
本文介绍了一项关于苄达明在阴道黏膜中的结合与分布的实验和临床研究结果,使用的是妇科用苄达明溶液。首先将其应用于大鼠时,其阴道黏膜中的药物平均含量为3.65±2.99微克/克新鲜组织,对照组和处理组动物之间存在显著差异,血浆中未检测到药物。应用于人体时,在17份阴道黏膜标本中检测到的苄达明平均含量为9.72±6.24微克/克。这一含量高于通过该药物药理研究确定的动物抗炎浓度范围(2 - 8微克/克),证明了苄达明治疗阴道炎症的局部疗效。在7名阴道健康的志愿者中检测苄达明,结果显示血浆中未检测到该药物。